Empliciti (elotuzumab) vs Talvey (talquetamab-tgvs)
Empliciti (elotuzumab) vs Talvey (talquetamab-tgvs)
Empliciti (elotuzumab) is a monoclonal antibody that targets the SLAMF7 protein on myeloma cells and is approved for use in combination with other medications for the treatment of multiple myeloma in patients who have received one to three prior therapies. Talquetamab-tgvs, known by its brand name Talzenna, is a bispecific antibody targeting both GPRC5D, a protein on myeloma cells, and CD3 on T-cells, and is being investigated in clinical trials for the treatment of relapsed or refractory multiple myeloma. When deciding between these two treatments, it is crucial to consider the specific characteristics of the disease, previous treatments, potential side effects, and the stage of clinical development, as Talquetamab-tgvs is not yet approved for use and is still under investigation.
Difference between Empliciti and Talvey
Metric | Empliciti (elotuzumab) | Talvey (talquetamab-tgvs) |
---|---|---|
Generic name | Elotuzumab | Talquetamab-tgvs |
Indications | Multiple myeloma (in combination with lenalidomide and dexamethasone) | Currently being investigated for the treatment of relapsed or refractory multiple myeloma |
Mechanism of action | SLAMF7-directed immunostimulatory antibody | GPRC5D x CD3 bispecific antibody |
Brand names | Empliciti | Talvey |
Administrative route | Intravenous infusion | Subcutaneous injection |
Side effects | Fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia | Currently under investigation; specific side effects in clinical trials are yet to be fully characterized |
Contraindications | Hypersensitivity to elotuzumab or any of its excipients | Not yet determined, as the drug is still in clinical trials |
Drug class | Monoclonal antibody | Bispecific antibody |
Manufacturer | Bristol-Myers Squibb | Janssen Biotech, Inc. |
Efficacy
Empliciti (Elotuzumab) Efficacy in Multiple Myeloma
Empliciti, known generically as elotuzumab, is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. It is specifically indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. The efficacy of Empliciti in this combination was demonstrated in a pivotal phase III clinical trial known as ELOQUENT-2. In this study, the addition of Empliciti to lenalidomide/dexamethasone significantly improved progression-free survival (PFS) compared to lenalidomide/dexamethasone alone. Patients treated with the Empliciti combination showed a median PFS of 19.4 months versus 14.9 months in the control group, which was a statistically significant improvement.
Talquetamab-tgvs (Talvey) Efficacy in Multiple Myeloma
Talvey, with the generic name talquetamab-tgvs, is an investigational bispecific antibody targeting GPRC5D, a novel target on multiple myeloma cells, and CD3 on T cells. As of the knowledge cutoff date, Talvey is not yet approved for use but has shown promise in early clinical trials. In a phase I study, talquetamab-tgvs demonstrated encouraging efficacy in heavily pretreated patients with relapsed or refractory multiple myeloma. The results indicated that talquetamab-tgvs, administered as a monotherapy, provided a clinically meaningful response in a significant proportion of patients, with some achieving stringent complete responses.
The exact efficacy rates and response durations for Talvey are subject to ongoing research and the outcomes of larger, confirmatory clinical trials. As an investigational drug, it is important to note that the safety and efficacy of Talvey for the treatment of multiple myeloma are not yet fully established and it remains under clinical development. The potential approval and use of Talvey will depend on the results of these trials and the evaluation of the risk-benefit profile by regulatory authorities.
In conclusion, Empliciti has established efficacy as part of a combination treatment for multiple myeloma patients who have received prior therapies, while Talvey is a promising new agent that is still under investigation. The continued development of these and other targeted therapies is critical for improving outcomes in multiple myeloma, particularly for patients who have exhausted other treatment options.
Regulatory Agency Approvals
Empliciti
Talvey
Access Empliciti or Talvey today
If Empliciti or Talvey are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us